These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 36602784)

  • 1. Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials.
    Fernandez-Martinez A; Pascual T; Singh B; Nuciforo P; Rashid NU; Ballman KV; Campbell JD; Hoadley KA; Spears PA; Pare L; Brasó-Maristany F; Chic N; Krop I; Partridge A; Cortés J; Llombart-Cussac A; Prat A; Perou CM; Carey LA
    JAMA Oncol; 2023 Apr; 9(4):490-499. PubMed ID: 36602784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.
    Fernandez-Martinez A; Rediti M; Tang G; Pascual T; Hoadley KA; Venet D; Rashid NU; Spears PA; Islam MN; El-Abed S; Bliss J; Lambertini M; Di Cosimo S; Huobe J; Goerlitz D; Hu R; Lucas PC; Swain SM; Sotiriou C; Perou CM; Carey LA
    JAMA Oncol; 2024 May; 10(5):603-611. PubMed ID: 38546612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
    Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
    JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Liu S; Chen B; Burugu S; Leung S; Gao D; Virk S; Kos Z; Parulekar WR; Shepherd L; Gelmon KA; Nielsen TO
    JAMA Oncol; 2017 Nov; 3(11):e172085. PubMed ID: 28750133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade.
    Nuciforo P; Pascual T; Cortés J; Llombart-Cussac A; Fasani R; Paré L; Oliveira M; Galvan P; Martínez N; Bermejo B; Vidal M; Pernas S; López R; Muñoz M; Garau I; Manso L; Alarcón J; Martínez E; Rodrik-Outmezguine V; Brase JC; Villagrasa P; Prat A; Holgado E
    Ann Oncol; 2018 Jan; 29(1):170-177. PubMed ID: 29045543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.
    Fernandez-Martinez A; Krop IE; Hillman DW; Polley MY; Parker JS; Huebner L; Hoadley KA; Shepherd J; Tolaney S; Henry NL; Dang C; Harris L; Berry D; Hahn O; Hudis C; Winer E; Partridge A; Perou CM; Carey LA
    J Clin Oncol; 2020 Dec; 38(35):4184-4193. PubMed ID: 33095682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.
    Carey LA; Berry DA; Cirrincione CT; Barry WT; Pitcher BN; Harris LN; Ollila DW; Krop IE; Henry NL; Weckstein DJ; Anders CK; Singh B; Hoadley KA; Iglesia M; Cheang MC; Perou CM; Winer EP; Hudis CA
    J Clin Oncol; 2016 Feb; 34(6):542-9. PubMed ID: 26527775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial.
    Dieci MV; Prat A; Tagliafico E; Paré L; Ficarra G; Bisagni G; Piacentini F; Generali DG; Conte P; Guarneri V
    Ann Oncol; 2016 Oct; 27(10):1867-73. PubMed ID: 27484801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer.
    Zagami P; Fernandez-Martinez A; Rashid NU; Hoadley KA; Spears PA; Curigliano G; Perou CM; Carey LA
    JAMA Netw Open; 2023 Dec; 6(12):e2348814. PubMed ID: 38117494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade.
    Prat A; Pascual T; De Angelis C; Gutierrez C; Llombart-Cussac A; Wang T; Cortés J; Rexer B; Paré L; Forero A; Wolff AC; Morales S; Adamo B; Brasó-Maristany F; Vidal M; Veeraraghavan J; Krop I; Galván P; Pavlick AC; Bermejo B; Izquierdo M; Rodrik-Outmezguine V; Reis-Filho JS; Hilsenbeck SG; Oliveira M; Dieci MV; Griguolo G; Fasani R; Nuciforo P; Parker JS; Conte P; Schiff R; Guarneri V; Osborne CK; Rimawi MF
    J Natl Cancer Inst; 2020 Jan; 112(1):46-54. PubMed ID: 31037288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy.
    De Angelis C; Nagi C; Hoyt CC; Liu L; Roman K; Wang C; Zheng Y; Veeraraghavan J; Sethunath V; Nuciforo P; Wang T; Tsimelzon A; Mao S; Hilsenbeck SG; Trivedi MV; Cataldo ML; Pavlick A; Wolff AC; Weigelt B; Reis-Filho JS; Prat A; Gutierrez C; Osborne CK; Rimawi MF; Schiff R
    Clin Cancer Res; 2020 Feb; 26(3):738-745. PubMed ID: 31653641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.
    Tanioka M; Fan C; Parker JS; Hoadley KA; Hu Z; Li Y; Hyslop TM; Pitcher BN; Soloway MG; Spears PA; Henry LN; Tolaney S; Dang CT; Krop IE; Harris LN; Berry DA; Mardis ER; Winer EP; Hudis CA; Carey LA; Perou CM
    Clin Cancer Res; 2018 Nov; 24(21):5292-5304. PubMed ID: 30037817
    [No Abstract]   [Full Text] [Related]  

  • 14. Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.
    Solinas C; Ceppi M; Lambertini M; Scartozzi M; Buisseret L; Garaud S; Fumagalli D; de Azambuja E; Salgado R; Sotiriou C; Willard-Gallo K; Ignatiadis M
    Cancer Treat Rev; 2017 Jun; 57():8-15. PubMed ID: 28525810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.
    Liu S; Duan X; Xu L; Xin L; Cheng Y; Liu Q; Ye J; Zhang S; Zhang H; Zhu S; Li T; Liu Y
    Breast Cancer Res Treat; 2015 Nov; 154(2):239-49. PubMed ID: 26498019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
    Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
    Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial.
    Powles RL; Redmond D; Sotiriou C; Loi S; Fumagalli D; Nuciforo P; Harbeck N; de Azambuja E; Sarp S; Di Cosimo S; Huober J; Baselga J; Piccart-Gebhart M; Elemento O; Pusztai L; Hatzis C
    JAMA Oncol; 2018 Nov; 4(11):e181564. PubMed ID: 29902299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.
    Huober J; Holmes E; Baselga J; de Azambuja E; Untch M; Fumagalli D; Sarp S; Lang I; Smith I; Boyle F; Xu B; Lecocq C; Wildiers H; Jouannaud C; Hackman J; Dasappa L; Ciruelos E; Toral Pena JC; Adamchuk H; Hickish T; de la Pena L; Jackisch C; Gelber RD; Piccart-Gebhart M; Di Cosimo S
    Eur J Cancer; 2019 Sep; 118():169-177. PubMed ID: 31377477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
    Luen SJ; Salgado R; Fox S; Savas P; Eng-Wong J; Clark E; Kiermaier A; Swain SM; Baselga J; Michiels S; Loi S
    Lancet Oncol; 2017 Jan; 18(1):52-62. PubMed ID: 27964843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy.
    Ignatiadis M; Van den Eynden G; Roberto S; Fornili M; Bareche Y; Desmedt C; Rothé F; Maetens M; Venet D; Holgado E; McNally V; Kiermaier A; Savage HM; Wilson TR; Cortes J; Schneeweiss A; Willard-Gallo K; Biganzoli E; Sotiriou C
    J Natl Cancer Inst; 2019 Jan; 111(1):69-77. PubMed ID: 29788230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.